TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35023363

Group type: EXPERIMENTAL
Intervention: Pericoronary FAI values >-70.1 Hounsfield units
Number of subjects: 130

Group type: COMPARATOR
Intervention: Lesions with pericoronary FAI values <=-70.1 Hounsfield units
Number of subjects: 130
Study: 35023844

Group type: EXPERIMENTAL
Intervention: Digital stories (2- to 3-minute self-made videos)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Video testimonies (created by professional filmmakers)
Number of subjects: 0
Study: 35024196

Group type: EXPERIMENTAL
Intervention: Microbiome-based predictive model
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Microbiome data added to clinical parameters
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Microbiome-based risk score including the ten most discriminant genera
Number of subjects: 462
Study: 35024375

Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 100
Study: 35024776

Group type: EXPERIMENTAL
Intervention: Natamycin
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 651
Study: 35025062

Group type: EXPERIMENTAL
Intervention: Deucravacitinib (3 mg twice daily, 6 mg twice daily, 12 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35025128

Group type: EXPERIMENTAL
Intervention: Non-O blood group
Number of subjects: 1789

Group type: COMPARATOR
Intervention: Group O
Number of subjects: 1789
Study: 35025555

Group type: EXPERIMENTAL
Intervention: Smartphone-delivered attentional bias modification (ABM) training for 13 days as an adjunct to smoking cessation treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 35025756

Group type: EXPERIMENTAL
Intervention: Antihyperglycemics
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Self-reported severe and nonsevere hypoglycemia incidence
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Self-reported hypoglycemia data
Number of subjects: 521
Study: 35025762

Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inosine supplementation
Number of subjects: 0
Study: 35025898

Group type: EXPERIMENTAL
Intervention: Collaborative care approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Telesupport approach
Number of subjects: 0
Study: 35025909

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Viral load monitoring
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HIV partner notification services
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Provision of pre-exposure prophylaxis (PrEP)
Number of subjects: 24
Study: 35025987

Group type: EXPERIMENTAL
Intervention: Micra leadless pacemaker implantation
Number of subjects: 2817
Study: 35026142

Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400 mg) and velpatasvir (100 mg) once daily for 12 weeks
Number of subjects: 399
Study: 35026411

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib
Number of subjects: 36
Study: 35026476

Group type: EXPERIMENTAL
Intervention: Lorlatinib (LBPD) continued beyond progressive disease
Number of subjects: 102
Study: 35026597

Group type: EXPERIMENTAL
Intervention: Working memory
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Clinical insight
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Positive symptoms
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 404
Study: 35026992

Group type: EXPERIMENTAL
Intervention: Predictive nomogram for postoperative AKI
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Summary risk score
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Calibration of nomogram
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Decision curve analysis
Number of subjects: 843
Study: 35027018

Group type: EXPERIMENTAL
Intervention: Low social acceptance among peers
Number of subjects: 775

Group type: COMPARATOR
Intervention: Psychological distress
Number of subjects: 775
Study: 35027038

Group type: EXPERIMENTAL
Intervention: Glucarpidase 2000u
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Glucarpidase 1000u
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Treatment with glucarpidase
Number of subjects: 8

Group type: COMPARATOR
Intervention: MTX-based therapy
Number of subjects: 8
Study: 35027051

Group type: EXPERIMENTAL
Intervention: cfDNA-based HCC screening model
Number of subjects: 120

Group type: COMPARATOR
Intervention: serum α-fetoprotein (AFP)
Number of subjects: 120
Study: 35027114

Group type: EXPERIMENTAL
Intervention: Icosapent Ethyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Background Statin Type
Number of subjects: 0
Study: 35027313

Group type: EXPERIMENTAL
Intervention: Combination of DNA-damaging therapy and immunotherapy
Number of subjects: 0
Study: 35027438

Group type: EXPERIMENTAL
Intervention: COVID-19 cohort (507 girls)
Number of subjects: 910

Group type: COMPARATOR
Intervention: Pre-COVID-19 cohort (403 girls)
Number of subjects: 910
Study: 35027474

Group type: EXPERIMENTAL
Intervention: New CVS+ lesions
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhancing lesions
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Higher CVS+ percentage at baseline
Number of subjects: 153
Study: 35027656

Group type: EXPERIMENTAL
Intervention: cfDNA positivity (≥10% tumor fraction by LPWGS) after two cycles of treatment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: cfDNA negativity (tumor-negative) after two cycles of treatment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: cfDNA as an independent risk factor
Number of subjects: 45
Study: 35027752

Group type: EXPERIMENTAL
Intervention: Olpasiran (9 mg or higher)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olpasiran (single doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olpasiran (dose-escalation trial)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olpasiran (in transgenic mice and cynomolgus monkeys)
Number of subjects: 0
Study: 35027909

Group type: EXPERIMENTAL
Intervention: A1c ≥7%
Number of subjects: 217

Group type: COMPARATOR
Intervention: A1c <7%
Number of subjects: 217
Study: 35028514

Group type: EXPERIMENTAL
Intervention: Trained champions in nutrition care improvements
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Implementation toolkit, audit and feedback, community of practice with external mentorship
Number of subjects: 14
Study: 35028608

Group type: EXPERIMENTAL
Intervention: PEC-01 cells implanted subcutaneously in VC-02 macroencapsulation devices
Number of subjects: 17
Study: 35028659

Group type: EXPERIMENTAL
Intervention: Bedaquiline and/or Delamanid
Number of subjects: 2296

Group type: EXPERIMENTAL
Intervention: Injectables
Number of subjects: 2296

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 2296
Study: 35028673

Group type: EXPERIMENTAL
Intervention: Antibiotics and caffeine among preterm infants
Number of subjects: 624249

Group type: EXPERIMENTAL
Intervention: Surfactant, caffeine, and probiotics
Number of subjects: 624249

Group type: EXPERIMENTAL
Intervention: Domperidone and ranitidine
Number of subjects: 624249

Group type: EXPERIMENTAL
Intervention: General drug utilisation patterns
Number of subjects: 624249

Group type: EXPERIMENTAL
Intervention: Non-evidence-based drugs
Number of subjects: 624249

Group type: EXPERIMENTAL
Intervention: Rational drug use
Number of subjects: 624249
Study: 35028730

Group type: EXPERIMENTAL
Intervention: sCMV
Number of subjects: 54

Group type: COMPARATOR
Intervention: CTL
Number of subjects: 54
Study: 35029044

Group type: EXPERIMENTAL
Intervention: Liver volume (LV) based prediction model (LEAP-HBV)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Estimated liver volume (ELV)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 486
Study: 35029189

Group type: EXPERIMENTAL
Intervention: upadacitinib plus methotrexate (MTX)
Number of subjects: 155
Study: 35029517

Group type: EXPERIMENTAL
Intervention: MB SENSE DWI
Number of subjects: 0

Group type: COMPARATOR
Intervention: cDWI
Number of subjects: 0
Study: 35029534

Group type: EXPERIMENTAL
Intervention: Wireless blood alcohol concentration device
Number of subjects: 0

Group type: COMPARATOR
Intervention: No access to the breathalyzer (Control)
Number of subjects: 0
Study: 35029661

Group type: EXPERIMENTAL
Intervention: Free-living gait cadence measured by wearable accelerometers
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Free-living gait cadence measured by wearable accelerometers in higher-functioning participants (cadence ≥100 steps/minute)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Traditional in-clinic measures of mobility
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: All metrics in participants with slow baseline gait (gait speed <0.8 m/s)
Number of subjects: 432
Study: 35029841

Group type: EXPERIMENTAL
Intervention: Customised foot orthoses (CFOs)
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses (PFOs)
Number of subjects: 1058
Study: 35029868

Group type: EXPERIMENTAL
Intervention: Insertion of subarachnoid oxygen electrode, pressure probe, and microdialysis catheter.
Number of subjects: 26
Study: 35030070

Group type: EXPERIMENTAL
Intervention: Pulmonary Magnetic Resonance Imaging (MRI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without BPD)
Number of subjects: 0
Study: 35030090

Group type: EXPERIMENTAL
Intervention: Tumaini smartphone game
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Brainilis control game
Number of subjects: 1004
Study: 35030234

Group type: EXPERIMENTAL
Intervention: 200,000 IU Vitamin A Supplementation (VAS) administered before and 4 weeks after measurement
Number of subjects: 94
Study: 35030235

Group type: EXPERIMENTAL
Intervention: Humanoid avatars generated for representative adults with characteristics based on body mass, height, age, and waist circumference
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Humanoid avatars developed at ∼20-y intervals for representative males and females
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Additional series of developed avatars at key BMI cutoffs
Number of subjects: 570
Study: 35031072

Group type: EXPERIMENTAL
Intervention: Multimodal chiropractic care
Number of subjects: 40
Study: 35031227

Group type: EXPERIMENTAL
Intervention: Obinutuzumab 1000 mg IV in cycle 1, followed by obinutuzumab plus atezolizumab 1200 mg IV for cycles 2-8, and atezolizumab only from cycle 9.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus atezolizumab 1200 mg IV
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg IV every 3 weeks (RP2D)
Number of subjects: 49
Study: 35031416

Group type: EXPERIMENTAL
Intervention: Rhinovirus A16 inoculation in subjects with allergic rhinitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rhinovirus A16 inoculation in subjects with asthma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls inoculated with rhinovirus A16
Number of subjects: 0
Study: 35031545

Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg/day plus Nivolumab 3 mg/kg every 2 weeks
Number of subjects: 30
Study: 35031547

Group type: EXPERIMENTAL
Intervention: NT-I7 (10 mg/kg on the final day of RT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RT (1.8 Gy/day × 5 days) + NT-I7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NT-I7
Number of subjects: 0

Group type: COMPARATOR
Intervention: Depleting CD8 T cells
Number of subjects: 0
Study: 35032132

Group type: EXPERIMENTAL
Intervention: Fetoscopic endoluminal tracheal occlusion (FETO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35032246

Group type: EXPERIMENTAL
Intervention: Community support for health care providers measuring alcohol consumption
Number of subjects: 260
Study: 35032562

Group type: EXPERIMENTAL
Intervention: Duodenal mucosal resurfacing (DMR)
Number of subjects: 34
Study: 35032664

Group type: EXPERIMENTAL
Intervention: Daraja intervention (five sessions delivered by a social worker over a 3-month period)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard of care HIV linkage
Number of subjects: 500
Study: 35032682

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Healthy Control
Number of subjects: 106
Study: 35032696

Group type: EXPERIMENTAL
Intervention: Fundal height measurement during routine antenatal visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound during routine antenatal visits
Number of subjects: 0
Study: 35032916

Group type: EXPERIMENTAL
Intervention: modified Baecke Physical Activity Questionnaire (mBQ)
Number of subjects: 100
Study: 35033008

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy (nCRT) using MRI guided radiotherapy (MRgRT) with 55 Gy in 25 fractions on Gross Tumor Volume (GTV) and 45 Gy in 25 fractions on drainage nodes, along with continuous chemotherapy with 5-fluoracil (5-FU) or oral capecitabine.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MRI guided radiotherapy (MRgRT) with dose escalation based on early tumour regression index (ERI).
Number of subjects: 0
Study: 35033042

Group type: EXPERIMENTAL
Intervention: Musculoskeletal radiologists and orthopaedic spine surgeons evaluating MRI findings
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Evaluation of dural sac cross-sectional area
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement for all parameters
Number of subjects: 102
Study: 35033047

Group type: EXPERIMENTAL
Intervention: New toric intraocular lens (IOL) with anchor-wing haptics (NS60YT)
Number of subjects: 53
Study: 35033055

Group type: EXPERIMENTAL
Intervention: PASHOS Test (clinical test including body mass index, neck circumference, and observed apneas during sleep)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: PASHOS Test with added oxygen desaturation index (ODI) from HSAT (ODI3% ≥ 15%)
Number of subjects: 194
Study: 35033092

Group type: EXPERIMENTAL
Intervention: Raltegravir 1200 mg once daily (qd) as part of triple combined antiretroviral therapy (cART)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Raltegravir 1200 mg qd
Number of subjects: 100
Study: 35033176

Group type: EXPERIMENTAL
Intervention: Music & Memory (M&M) intervention implemented using a standardized manual, staff trainings, and iPods for residents.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Music & Memory (M&M) intervention
Number of subjects: 27
Study: 35033178

Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 40

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 40
Study: 35033182

Group type: EXPERIMENTAL
Intervention: Dexamethasone 20 mg on days 1-5, followed by dexamethasone 10 mg on days 6-10
Number of subjects: 300

Group type: COMPARATOR
Intervention: Dexamethasone 6 mg administered once daily intravenously for 10 days
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Dexamethasone 20 mg
Number of subjects: 300

Group type: COMPARATOR
Intervention: Dexamethasone 6 mg
Number of subjects: 300
Study: 35033490

Group type: EXPERIMENTAL
Intervention: Myocardial perfusion reserve (MPR) in patients with HFpEF
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Microvascular dysfunction (MVD) in patients with HFpEF
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Composite events in HFpEF group during follow-up
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: MPR as a predictor of clinical outcome in HFpEF
Number of subjects: 101
Study: 35033495

Group type: EXPERIMENTAL
Intervention: 18F-GP1 PET-CT
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Anticoagulation for 3 months
Number of subjects: 75
Study: 35033576

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphism-based prenatal cell-free DNA screening
Number of subjects: 20887

Group type: EXPERIMENTAL
Intervention: Updated cell-free DNA algorithm
Number of subjects: 20887
Study: 35033577

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in young patients
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: All-cause mortality in young patients
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Myocardial infarction in young patients
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Any revascularization in young patients
Number of subjects: 472
Study: 35033999

Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Nonbiologic disease-modifying antirheumatic drugs (nbDMARDs)
Number of subjects: 425
Study: 35034046

Group type: EXPERIMENTAL
Intervention: Budigalimab 250 mg Q2W or 500 mg Q4W
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Budigalimab
Number of subjects: 81
Study: 35034080

Group type: EXPERIMENTAL
Intervention: Hypertension treatment at registration
Number of subjects: 4927

Group type: EXPERIMENTAL
Intervention: Hypertension treatment at the end of the baseline visit
Number of subjects: 4927

Group type: EXPERIMENTAL
Intervention: Hypertension control rate
Number of subjects: 4927

Group type: EXPERIMENTAL
Intervention: Factors associated with hypertension control
Number of subjects: 4927
Study: 35034096

Group type: EXPERIMENTAL
Intervention: Noninvasive respiratory support for a median duration of 18 days
Number of subjects: 6268

Group type: EXPERIMENTAL
Intervention: Noninvasive respiratory support
Number of subjects: 6268
Study: 35034116

Group type: EXPERIMENTAL
Intervention: Weight Loss (WL) + lower Aβ 42/40 (≤0.103, lowest quartile)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Weight Loss (WL) + higher NfL (>94.55 pg/mL, highest quartile)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Weight Loss (WL) + higher progranulin (>38.4 ng/mL, 3 higher quartiles)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Weight Loss (WL) + lower progranulin (Q1-Q3)
Number of subjects: 470
Study: 35034320

Group type: EXPERIMENTAL
Intervention: Microvascular involvement signs (TIB and VEP)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: High extension of VEP and TIB
Number of subjects: 139
Study: 35034655

Group type: EXPERIMENTAL
Intervention: DuraGraft (DG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (S)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Heparinized Blood (HB)
Number of subjects: 50
Study: 35035223

Group type: EXPERIMENTAL
Intervention: Meropenem treatment
Number of subjects: 58
Study: 35035233

Group type: EXPERIMENTAL
Intervention: TAP-DEX group (bupivacaine + 1 µg/kg dexmedetomidine)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: TAP-DEX group
Number of subjects: 24

Group type: COMPARATOR
Intervention: TAP group
Number of subjects: 24
Study: 35035955

Group type: EXPERIMENTAL
Intervention: CoV2-PreS-dTM with AS03
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: CoV2-PreS-dTM with AF03
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 90
Study: 35036077

Group type: EXPERIMENTAL
Intervention: Combined radiotherapy and anti-PD-1 antibody camrelizumab
Number of subjects: 34
Study: 35036831

Group type: EXPERIMENTAL
Intervention: Ketamine as an adjunctive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketamine as an adjunctive therapy for major depression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 35036998

Group type: EXPERIMENTAL
Intervention: digi-physical eVisits
Number of subjects: 281

Group type: COMPARATOR
Intervention: office visits
Number of subjects: 281
Study: 35037034

Group type: EXPERIMENTAL
Intervention: Higher plasma GDF15 levels
Number of subjects: 1096

Group type: EXPERIMENTAL
Intervention: GDF15 cutoff values
Number of subjects: 1096
Study: 35037052

Group type: EXPERIMENTAL
Intervention: High physical activity (PA)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Low physical activity (PA)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Continuous BMI
Number of subjects: 512
Study: 35037228

Group type: EXPERIMENTAL
Intervention: Correction of hyponatremia (Na levels increased by 1, 5, and 10 mmol/L)
Number of subjects: 3880

Group type: EXPERIMENTAL
Intervention: Noncorrection of hyponatremia on days 4 and 7
Number of subjects: 3880
Study: 35037887

Group type: EXPERIMENTAL
Intervention: Remote glucose monitoring using Bluetooth-capable glucose meters and Apple iPod Touch devices.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care involving keeping written records of glucose values and contacting the diabetes team daily by telephone.
Number of subjects: 40
Study: 35037892

Group type: EXPERIMENTAL
Intervention: Aerobic exercise group (10-week training program, 3 times per week)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: High-intensity interval training group (10-week training program, 3 times per week)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (participation in other physical activities during the same intervention period)
Number of subjects: 78
Study: 35037893

Group type: EXPERIMENTAL
Intervention: Diet with low total carbohydrate content
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Diet combining low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols and traditional dietary advice
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Optimized medical treatment
Number of subjects: 300
Study: 35038821

Group type: EXPERIMENTAL
Intervention: MOS methylation high group (≥ 34.82%)
Number of subjects: 294

Group type: COMPARATOR
Intervention: MOS methylation low group
Number of subjects: 294

Group type: COMPARATOR
Intervention: OLGA or OLGIM stages
Number of subjects: 294
Study: 35038983

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg PRN
Number of subjects: 1044
Study: 35039050

Group type: EXPERIMENTAL
Intervention: Beacon Caresystem (personalised mechanical ventilation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard routine care (control)
Number of subjects: 0
Study: 35039057

Group type: EXPERIMENTAL
Intervention: Enhanced participant information leaflet (PIL/ICF) and a website with animations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard participant information leaflet (PIL/ICF)
Number of subjects: 0
Study: 35039091

Group type: EXPERIMENTAL
Intervention: Losmapimod (intervention from the ReDUX4 trial)
Number of subjects: 0
Study: 35039142

Group type: EXPERIMENTAL
Intervention: Ginger (Zingiberofficinale) add-on therapy, 399 mg three times per day for 6 weeks
Number of subjects: 21